{"id":"add-glimepiride","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"2–5","effect":"Weight gain"},{"rate":"1–3","effect":"Dizziness"},{"rate":"1–3","effect":"Headache"},{"rate":"1–3","effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose levels in patients with type 2 diabetes by increasing endogenous insulin secretion.","oneSentence":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:35.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT04183868","phase":"PHASE4","title":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","status":"COMPLETED","sponsor":"University of Catanzaro","startDate":"2016-04","conditions":"Type 2 Diabetes, Cardiovascular Risk Factor","enrollment":26},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03332771","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":954},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":800},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT03060980","phase":"PHASE3","title":"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2017-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":34},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02567994","phase":"PHASE3","title":"Tenelia Triple Combination Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-04","conditions":"Type 2 Diabetes Mellitus","enrollment":201},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT02954822","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-11-14","conditions":"Type2 Diabetes","enrollment":36},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00032487","phase":"PHASE3","title":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2000-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1791},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00701090","phase":"PHASE3","title":"A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":1035},{"nctId":"NCT00614120","phase":"PHASE3","title":"Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT01233622","phase":"PHASE3","title":"Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00968812","phase":"PHASE3","title":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1452},{"nctId":"NCT00331851","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":584},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01649466","phase":"PHASE4","title":"Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":162},{"nctId":"NCT02946632","phase":"PHASE3","title":"Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2016-12","conditions":"Diabetes Mellitus, Type II","enrollment":104},{"nctId":"NCT01829477","phase":"PHASE3","title":"Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-04","conditions":"Diabetes Mellitus, Type 2","enrollment":33},{"nctId":"NCT01990469","phase":"PHASE3","title":"Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-01","conditions":"T2DM","enrollment":219},{"nctId":"NCT02026310","phase":"NA","title":"Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment","status":"COMPLETED","sponsor":"Qifu Li","startDate":"2014-01","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01769378","phase":"PHASE3","title":"Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT01910441","phase":"PHASE4","title":"Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":95},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":3371},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT02426294","phase":"PHASE4","title":"Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT01494987","phase":"PHASE3","title":"Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":431},{"nctId":"NCT00309608","phase":"PHASE2","title":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":333},{"nctId":"NCT01099137","phase":"PHASE4","title":"Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Diabetes","enrollment":344},{"nctId":"NCT01357252","phase":"PHASE3","title":"Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Type 2 Diabetes Mellitus","enrollment":279},{"nctId":"NCT02089126","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus","enrollment":230},{"nctId":"NCT01195259","phase":"","title":"Malignancy Meta Analysis for BRL49653","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT01455883","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Intarcia Therapeutics","startDate":"2013-02","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01455922","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Intarcia Therapeutics","startDate":"2013-02","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT00975065","phase":"PHASE4","title":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":266},{"nctId":"NCT00908921","phase":"PHASE4","title":"Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Diabetes Mellitus, Type 2","enrollment":391},{"nctId":"NCT00562172","phase":"PHASE4","title":"Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT01624116","phase":"NA","title":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2011-08","conditions":"Diabetes, Type 2","enrollment":161},{"nctId":"NCT00363519","phase":"PHASE3","title":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2006-08","conditions":"Type 2 Diabetes Mellitus","enrollment":195},{"nctId":"NCT01547104","phase":"PHASE4","title":"Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Marcus Borchert","startDate":"2012-04","conditions":"Diabetes Mellitus Type 2","enrollment":40},{"nctId":"NCT01509001","phase":"PHASE4","title":"Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-01","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT00044447","phase":"PHASE3","title":"Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":124,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Add Glimepiride","genericName":"Add Glimepiride","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}